Sementis is at the leading edge of vaccine development, with the Sementis Copenhagen Vector system currently Australia’s most advanced non-replicating viral vector vaccine platform technology.
To date, the SCV platform system has demonstrated the ability to generate strong, broad, and long lasting protective immune responses in animal models after a single dose of a multi-disease vaccine. This includes the ability to protect against disease in higher order animal challenge models, thus paving the way to enter Phase I clinical trials.
